Beam Therapeutics BEAM EBIT

EBIT at other companies

Vertex PharmaceuticalsVRTX

$1.25B+8.3%

Arrowhead ResearchARWR

-$141.26M-137%

Ultragenyx PharmaceuticalRARE

-$75M+30.6%

MGN

MagniteMGNI

$31.22M+42.2%

Wave Life SciencesWVE

-$73.8M-39.9%

Intellia TherapeuticsNTLA

-$112.76M-2.5%

FAQ

What is Beam Therapeutics's EBIT?

Beam Therapeutics (BEAM) reported EBIT of -$107.22M in Q1 2026.

How has Beam Therapeutics's EBIT changed year-over-year?

Beam Therapeutics's EBIT increased by 10.1% year-over-year, from -$119.29M to -$107.22M.

What is the long-term trend for Beam Therapeutics's EBIT?

Over 3 years (2021 to 2025), Beam Therapeutics's EBIT has grown at a -0.8% compound annual growth rate (CAGR), from -$392.47M to -$383.69M.

What does EBIT mean?

Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.